Skip to main content

Day: August 31, 2022

MT Højgaard Holding A/S: MT Højgaard Danmark and N.V. BESIX S.A. awarded conditional DKK 2.6 bn contract for construction of the Nordhavn tunnel

MT Højgaard Holding’s business unit MT Højgaard Danmark and Belgian joint venture partner N.V. BESIX S.A. have entered a conditional contract with the Danish Road Directorate for the construction of the Nordhavn tunnel in Copenhagen. The contract value is DKK 2,585 million, and signing is expected after expiration of the standstill period in mid-September 2022. Planning and construction of the building site by Svanemøllen bay will commence immediately after signing of the contract. The joint venture partners N.V. BESIX S.A. and MT Højgaard Danmark will collaborate closely with suppliers Niras, Bravida Danmark and Jacobs Sverige AB for the construction of the Nordhavn tunnel, which is to be commissioned in 2027 and ensure more direct access to the developing areas in the outer and inner Nordhavn. The tunnel will connect Østerbro with outer...

Continue reading

Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following:More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval.Eligibility for Accelerated Approval or Priority Review, if relevant criteria are met.Rolling Review, which means that Scilex can submit completed sections of its New Drug Application (NDA) for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed.Despite an overall lack of evidence to support their efficacy, opioids continue to be prescribed to treat acute LBP when patients seek medical evaluation. According to the CDC in 2020, LBP was the most common type of pain reported by patients,...

Continue reading

UPDATE — Privia Health Reports Results in CMS’ Medicare Shared Savings Program

2021 Performance Across All Markets Demonstrates Improved Care and Lower Costs Privia ACOs Delivered Total Annual Average Expenditures 15% Lower than Median MSSP ACO and 24% Lower than Total Fee for Service Medicare $99.9 Million in Shared Savings Delivered across Georgia, Maryland, Texas, Virginia and Washington, DC ARLINGTON, Va., Aug. 30, 2022 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA) today announced that its Accountable Care Organizations (“ACOs”) delivered quality care and improved patient outcomes, and achieved shared savings of $99.9 million through the Medicare Shared Savings Program (“MSSP”). Privia’s ACOs (collectively “Privia Quality Network”) provided high-value, cost-efficient care to more than 112,000 Medicare beneficiaries in 2021. “Navigating care options for patients during the coronavirus pandemic...

Continue reading

XR Immersive Tech Announces Record Second Quarter Revenue & Corporate Update

VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) — XR Immersive Tech Inc. (“XRi” or “Immersive Tech”, or the “Company”) (CSE:VRAR) (FSE:79W) (OTCQB: FNTTF) a leading location-based virtual reality (“LBVR”) content distribution and facility management platform, today announced results for its second quarter and first half of its fiscal 2022 year ended June 30, 2022 as well as providing a mid-year corporate update. “We had a great second quarter, and first half of 2022, with revenues climbing sharply including a number of strategic key milestones reached which I am excited to share,” said Tim Bieber XRi CEO. XRi delivered the following results for its second quarter and first half of its fiscal 2022 year: In the Company’s second quarter revenue was $348,328 with associated cost of goods sold of $71,375, a revenue...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.